MALAT1 and cancer: Shuai et al. [24] performed a meta-analysis with a total of 2094 patients from 17 studies to assess the effects of MALAT1 on cancer prognosis and lymph nodes, and the results indicated that the upregulation of MALAT1 expression was significantly associated with poor disease-free survival (HR = 2.29, 95 % CI 1.24-3.35), and recurrence-free survival (HR = 2.09, 95 % CI 0.81-3.37).